# US 10,500,284 B2 · Pharmaceutical formulation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,500,284 B2 - Document ID: US10500284B2 - Status: Granted - Kind: B2 - Application number: 15/545,204 - Filed: 2016-01-20 - Published: 2018-01-11 - Granted: 2019-12-10 - Earliest claimed: 2015-01-21 - Assignees: Semnur Pharmaceuticals, Inc. - Applicants: Semnur Pharmaceuticals, Inc. - Inventors: Mahendra G. Shah - Web page: https://patentgrep.com/patent/US10500284B2 ## CPC - A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 9/0085: {Brain, e.g. brain implants; Spinal cord} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone - A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 47/02: Inorganic compounds - A61P 19/00: Drugs for skeletal disorders - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 19/04: for non-specific disorders of the connective tissue - A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents - A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease - A61P 25/04: Centrally acting analgesics, e.g. opioids - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Disclosed are aqueous pharmaceutical compositions which provide sustained released delivery of corticosteroid compounds. The pharmaceutical composition comprises a soluble corticosteroid and at least one viscosity enhancing agent. Also provided are methods for using the pharmaceutical compositions in an epidural injection, intra-articular injection, or an intra-lesional injection. ## Claims ### Claim 1 An injectable aqueous pharmaceutical composition comprising: a soluble corticosteroid selected from the group consisting of soluble salts and esters of dexamethasone; and at least one viscosity enhancing agent, wherein the at least one viscosity enhancing agent is sodium hyaluronate or hyaluronic acid, the molecular weight of the at least one viscosity enhancing agent is between 1.0 MDa and 2.5 MDa, and the concentration of the at least one viscosity enhancing agent is between 1.0% w/v and 1.5% w/v; and wherein the injectable aqueous pharmaceutical composition does not comprise insoluble dexamethasone acetate. ### Claim 2 (depends on 1) The injectable aqueous pharmaceutical composition of claim 1, wherein the soluble corticosteroid is dexamethasone sodium phosphate. ### Claim 3 (depends on 1) The injectable aqueous pharmaceutical composition of claim 1, wherein the at least one viscosity enhancing agent is hyaluronic acid. ### Claim 4 (depends on 1) The injectable aqueous pharmaceutical composition of claim 1, wherein the at least one viscosity enhancing agent is sodium hyaluronate. ### Claim 5 (depends on 1) The injectable aqueous pharmaceutical composition of claim 1, wherein the soluble corticosteroid is dexamethasone sodium phosphate and the at least one viscosity enhancing agent is sodium hyaluronate. ### Claim 6 (depends on 1) The injectable aqueous pharmaceutical composition of claim 1, wherein the concentration of the at least one viscosity enhancing agent is about 1.25% w/v. ### Claim 7 (depends on 1) The injectable aqueous pharmaceutical composition of claim 1, further comprising a preservative and/or an anesthetic. ### Claim 8 A syringe comprising an injectable aqueous pharmaceutical composition, wherein the injectable aqueous pharmaceutical composition comprises: a soluble corticosteroid selected from the group consisting of soluble salts and esters of dexamethasone; and at least one viscosity enhancing agent, wherein the at least one viscosity enhancing agent is sodium hyaluronate or hyaluronic acid, the molecular weight of the at least one viscosity enhancing agent is between 1.0 MDa and 2.5 MDa, and the concentration of the at least one viscosity enhancing agent is between 1.0% w/v and 1.5% w/v; and wherein the injectable aqueous pharmaceutical composition does not comprise insoluble dexamethasone acetate. ### Claim 9 (depends on 8) The syringe comprising an injectable aqueous pharmaceutical composition of claim 8, wherein the soluble corticosteroid is dexamethasone sodium phosphate. ### Claim 10 (depends on 8) The syringe comprising an injectable aqueous pharmaceutical composition of claim 8, wherein the injectable aqueous pharmaceutical composition comprises a soluble salt or ester of dexamethasone present at a weight equivalent to achieve a dexamethasone concentration of about 5 mg/mL. ### Claim 11 (depends on 8) The syringe comprising an injectable aqueous pharmaceutical composition of claim 8, wherein the at least one viscosity enhancing agent is hyaluronic acid. ### Claim 12 (depends on 8) The syringe comprising an injectable aqueous pharmaceutical composition of claim 8, wherein the at least one viscosity enhancing agent is sodium hyaluronate. ### Claim 13 (depends on 8) The syringe comprising an injectable aqueous pharmaceutical composition of claim 8, wherein the soluble corticosteroid is dexamethasone sodium phosphate and the at least one viscosity enhancing agent is sodium hyaluronate. ### Claim 14 (depends on 8) The syringe comprising an injectable aqueous pharmaceutical composition of claim 8, wherein the concentration of the at least one viscosity enhancing agent is about 1.25% w/v. ### Claim 15 (depends on 8) The syringe comprising an injectable aqueous pharmaceutical composition of claim 8, further comprising a preservative and/or an anesthetic. ### Claim 16 (depends on 1) The injectable aqueous pharmaceutical composition of claim 1, wherein the molecular weight of the at least one viscosity enhancing agent is between 1.0 MDa and 2.0 MDa. ### Claim 17 (depends on 1) The injectable aqueous pharmaceutical composition of claim 1, wherein the molecular weight of the at least one viscosity enhancing agent is between 1.2 MDa and 1.8 MDa. ### Claim 18 (depends on 1) The injectable aqueous pharmaceutical composition of claim 1, wherein the soluble corticosteroid is dexamethasone sodium phosphate and the at least one viscosity enhancing agent is sodium hyaluronate, wherein the molecular weight of the sodium hyaluronate is between 1.0 MDa and 2.0 MDa, and the concentration of the sodium hyaluronate is about 1.25% w/v. ### Claim 19 (depends on 18) The injectable aqueous pharmaceutical composition of claim 18, comprising dexamethasone sodium phosphate at a concentration of about 6.58 mg/mL. ### Claim 20 (depends on 1) The injectable aqueous pharmaceutical composition of claim 1, comprising a soluble salt or ester of dexamethasone present at a weight equivalent to achieve a dexamethasone concentration of about 5 mg/mL. ### Claim 21 (depends on 1) The injectable aqueous pharmaceutical composition of claim 1, having a viscosity of between 1 kcP and 10 kcP. ### Claim 22 (depends on 1) The injectable aqueous pharmaceutical composition of claim 1, having a viscosity of between 1 kcP and 5 kcP. ### Claim 23 (depends on 8) The syringe comprising an injectable aqueous pharmaceutical composition of claim 8, wherein the molecular weight of the at least one viscosity enhancing agent is between 1.0 MDa and 2.0 MDa. ### Claim 24 (depends on 8) The syringe comprising an injectable aqueous pharmaceutical composition of claim 8, wherein the molecular weight of the at least one viscosity enhancing agent is between 1.2 MDa and 1.8 MDa. ### Claim 25 (depends on 8) The syringe comprising an injectable aqueous pharmaceutical composition of claim 8, wherein the soluble corticosteroid is dexamethasone sodium phosphate and the at least one viscosity enhancing agent is sodium hyaluronate, wherein the molecular weight of the sodium hyaluronate is between 1.0 MDa and 2.0 MDa, and the concentration of the sodium hyaluronate is about 1.25% w/v. ### Claim 26 (depends on 25) The syringe comprising an injectable aqueous pharmaceutical composition of claim 25, comprising dexamethasone sodium phosphate at a concentration of about 6.58 mg/mL. ### Claim 27 (depends on 25) The syringe comprising an injectable aqueous pharmaceutical composition of claim 25, comprising dexamethasone sodium phosphate at a weight equivalent to achieve a dexamethasone concentration of about 5 mg/mL. ### Claim 28 (depends on 8) The syringe comprising an injectable aqueous pharmaceutical composition of claim 8, having a viscosity of between 1 kcP and 10 kcP. ### Claim 29 (depends on 8) The syringe comprising an injectable aqueous pharmaceutical composition of claim 8, having a viscosity of between 1 kcP and 5 kcP.